retatrutide dementia Could popular weight-loss drugs help treat addiction and dementia? What Patients Should Understand Before

3 Glucagon is the hormone most people associate with raising blood sugar, but it has a second function

Currently being evaluated for obesity and other metabolic indications

Hence, individualized treatment strategies, considering factors such as patient age, underlying comorbidities, and DPN severity, will be critical for optimizing therapeutic outcomes

Phase 2 trial: up to 24.2% weight loss at 48 weeks

Among non-elderly adults with ESI (estimated to be 116.8 million from NHIS), 42%, or 49.3 million people, are clinically eligible for GLP-1 drugs

In comparison, Semaglutide primarily targets GLP-1 receptors, while Tirzepatide targets both GLP-1 and GIP receptors